Introduction: Metastatic or inoperable NeuroEndocrine Neoplasms (NENs) are unresponsive to chemotherapy and targeted therapies. An emerging option is PRRT.
Aim(s): The purpose of this study is to assess the clinical, radiological and biochemical response, as well as the safety of PRRT.
Materials and methods: Thirty five (35) patients with histologically confirmed metastatic or unresectable NET were retrospectively studied. Overall response (OR) was recorded at 6 months and 2 years post treatment, incorporating both partial response (PR) and stable disease (SD). Toxicity was assessed by Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Theodora Liotsou
To read results and conclusion, please login ...
Further abstracts you may be interested in